0.01
-0.00469(-27.59%)
Currency In USD
| Previous Close | 0.02 |
| Open | 0.02 |
| Day High | 0.02 |
| Day Low | 0.01 |
| 52-Week High | 2.79 |
| 52-Week Low | 0.01 |
| Volume | 3.06M |
| Average Volume | 19.98M |
| Market Cap | 885,690 |
| PE | -0.05 |
| EPS | -0.23 |
| Moving Average 50 Days | 0.27 |
| Moving Average 200 Days | 0.95 |
| Change | -0 |
Data not available
IO Biotech Provides Corporate Update
GlobeNewswire Inc.
Jan 30, 2026 1:05 PM GMT
Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeut
IO Biotech Announces Exploration of Strategic Alternatives
GlobeNewswire Inc.
Jan 21, 2026 10:30 AM GMT
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
GlobeNewswire Inc.
Dec 15, 2025 9:05 PM GMT
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5 monthsThese results reinforce the poten